It depends on the peptide and how it's sold. Some peptides, like semaglutide, tirzepatide and tesamorelin, are FDA-approved drugs available with a prescription. Others, like BPC-157 and TB-500, are not FDA-approved. In 2026 the FDA removed 12 peptides from its list of compounding ingredients that raise significant safety concerns, and an FDA advisory committee recommended six of them for the list pharmacies can compound from. The FDA has not acted on that recommendation yet.

When will the FDA decide on BPC-157 and TB-500?

There is no announced date. The FDA must decide whether to accept the committee's nonbinding recommendation, and adding a substance to the 503A bulks list requires notice-and-comment rulemaking, which one analysis estimates can take 12 to 24 months.

Does removal from Category 2 mean a peptide is approved?

No. Removal from Category 2 does not, by itself, make a peptide eligible for compounding under Section 503A, and it does not make it an FDA-approved drug.

Are Peptides Legal? Peptide FDA Status Tracker (October 2026)

Q: Is BPC-157 FDA approved?

No. BPC-157 is not FDA-approved for any use. In April 2026 the FDA removed it from Category 2, and in July 2026 an FDA advisory committee recommended adding it to the 503A bulks list. The recommendation is advisory; the FDA must take additional action, including formal rulemaking, before it is added.

Peptide FDA Status Tracker

Last checked October 20, 2026

Where each peptide stands with the FDA after the 2026 changes, in plain English. Every status links to the source it comes from.

Are peptides legal? Short answer: it depends on the peptide and how it's sold.

Some peptides are FDA-approved drugs, like semaglutide, tirzepatide and tesamorelin. They're legal with a prescription.
In April 2026, the FDA took 12 peptides off its "significant safety concerns" list for compounding, including BPC-157 and TB-500. That did not make them approved drugs.
In July 2026, an FDA advisory committee recommended 6 of them for the list compounding pharmacies can use. The FDA hasn't acted on that yet, and formal rulemaking is still required.

Status of each peptide

FDA-approved drugApproved for specific uses. Prescription required.

Recommended, awaiting FDAAdvisory committee voted yes in July 2026. Not on the 503A list yet.

Under reviewOff the safety-concern list. Committee review expected before February 2027.

Not recommendedAdvisory committee voted against adding it.

Peptide	Status	What happened	Source
Semaglutide Ozempic, Wegovy, Rybelsus	FDA-approved drug	Approved for type 2 diabetes and, as Wegovy, for weight management. In February 2026 the FDA announced restrictions on the ingredients used in mass-marketed compounded versions.	Drugs@FDA, AJMC
Tirzepatide Mounjaro, Zepbound	FDA-approved drug	Approved for type 2 diabetes and, as Zepbound, for weight management. In February 2026 the FDA announced restrictions on the ingredients used in mass-marketed compounded versions.	Drugs@FDA, AJMC
Tesamorelin Egrifta	FDA-approved drug	Approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.	Drugs@FDA
BPC-157	Recommended, awaiting FDA	Removed from Category 2 in April 2026. On July 23, 2026, the advisory committee recommended adding it to the 503A bulks list. FDA scientific staff had recommended against it. Not FDA-approved for any use.	Goodwin, Frier Levitt
TB-500 Thymosin beta-4 fragment	Recommended, awaiting FDA	Removed from Category 2 in April 2026. Recommended for the 503A bulks list on July 23, 2026, against FDA staff's recommendation.	Goodwin, Frier Levitt
MOTS-c	Recommended, awaiting FDA	Removed from Category 2 in April 2026. Recommended for the 503A bulks list on July 23, 2026, against FDA staff's recommendation.	Goodwin, Frier Levitt
KPV	Recommended, awaiting FDA	Removed from Category 2 in April 2026. Recommended for the 503A bulks list on July 23, 2026, against FDA staff's recommendation.	Goodwin, Frier Levitt
Semax	Recommended, awaiting FDA	Removed from Category 2 in April 2026. Recommended for the 503A bulks list on July 24, 2026, against FDA staff's recommendation.	Goodwin, Frier Levitt
Epitalon	Recommended, awaiting FDA	Removed from Category 2 in April 2026. Recommended for the 503A bulks list on July 24, 2026, against FDA staff's recommendation.	Goodwin, Frier Levitt
GHK-Cu (injectable)	Under review	Injectable GHK-Cu was removed from Category 2 in April 2026, with a committee review expected before February 2027. Topical GHK-Cu in skincare is a separate cosmetic product.	Goodwin
LL-37 Cathelicidin	Under review	Removed from Category 2 in April 2026. Committee review expected before February 2027.	Goodwin
Dihexa	Under review	Removed from Category 2 in April 2026. Committee review expected before February 2027.	Goodwin
PEG-MGF Mechano growth factor	Under review	Removed from Category 2 in April 2026. Committee review expected before February 2027.	Goodwin
Melanotan II	Under review	Removed from Category 2 in April 2026. Committee review expected before February 2027.	Goodwin
DSIP Emideltide	Not recommended	Removed from Category 2 in April 2026. On July 24, 2026, the advisory committee recommended against adding it to the 503A bulks list.	Goodwin, Frier Levitt

We list a peptide only when we can cite its status to the FDA or a published legal analysis. Sources currently disagree on sermorelin, so it isn't listed yet.

2026 timeline

February 6, 2026
The FDA announced restrictions on the active ingredients used in mass-marketed compounded semaglutide and tirzepatide. AJMC
February 27, 2026
HHS Secretary Robert F. Kennedy Jr. announced that about 14 of the 19 peptides on the FDA's Category 2 list would be moved off it. AJMC
April 15, 2026
The FDA announced it would remove 12 peptides from Category 2 and scheduled an advisory committee meeting on seven of them. The removal took effect after a seven-day notice period. Goodwin
July 23–24, 2026
The Pharmacy Compounding Advisory Committee recommended 6 of the 7 peptides for the 503A bulks list and recommended against DSIP. FDA scientific staff had recommended against all seven. Frier Levitt
Before February 2027
A committee meeting is expected on five more peptides: LL-37, Dihexa, injectable GHK-Cu, PEG-MGF and Melanotan II. Goodwin
Next
The FDA decides whether to accept the July recommendations. Adding a substance to the 503A list requires notice-and-comment rulemaking, which can take 12 to 24 months. AJMC

What "Category 1" and "Category 2" mean

The FDA sorts ingredients that pharmacies have asked to compound with into categories while it evaluates them:

Category 1: nominated with enough information for the FDA to evaluate. While it does, the FDA doesn't intend to take action against pharmacies compounding with them, under certain conditions.
Category 2: the FDA has identified significant safety risks with compounding them and would consider enforcement action.
Category 3: nominated without enough information to evaluate.

Source: FDA, bulk drug substances used in compounding under Section 503A.

What is the 503A bulks list?

503A pharmacies compound medications for individual patients with a prescription. The 503A bulks list is the list of ingredients the FDA allows them to compound with beyond those that already have a USP monograph or are part of an FDA-approved drug. Getting a peptide onto that list is what the July 2026 votes were about.

Off Category 2 doesn't mean approved

This is the most common mistake in coverage of the 2026 changes. Removing a peptide from Category 2 does not, by itself, make it eligible for compounding under 503A, and it doesn't make it an FDA-approved drug. A committee recommendation doesn't either: the FDA still has to act, including through formal rulemaking.

What about "research use only" peptides?

Products labeled "research use only" or "not for human consumption" aren't FDA-approved drugs, and they aren't compounded medications prescribed to a patient. The 2026 changes on this page are about which ingredients compounding pharmacies may use. They don't change the status of research-use-only products.

Frequently asked questions

Is BPC-157 FDA approved?

No. BPC-157 isn't FDA-approved for any use. It was removed from Category 2 in April 2026, and an FDA advisory committee recommended it for the 503A bulks list in July 2026. The FDA hasn't acted on that recommendation.

Is TB-500 legal?

TB-500 isn't an FDA-approved drug. Like BPC-157, it came off Category 2 in April 2026 and was recommended for the 503A list in July 2026, and it's waiting on FDA action.

When will the FDA decide?

There's no announced date. The committee's vote is nonbinding, and adding a substance to the 503A list requires notice-and-comment rulemaking, which one analysis estimates can take 12 to 24 months.

Can my doctor prescribe BPC-157 now?

A committee recommendation doesn't place a peptide on the 503A list, so the July vote alone doesn't authorize pharmacies to compound it. Ask your doctor and pharmacist what they can legally provide today.

How often is this page updated?

We check it whenever the FDA announces a change and at least monthly. The "Last checked" date at the top shows the latest review. Spotted something out of date? Tell us.

Sources

FDA: Bulk drug substances used in compounding under Section 503A (content current as of May 14, 2026)
Goodwin: FDA signals potentially evolving stance toward compounding of certain peptides (May 2026)
Frier Levitt: FDA PCAC peptide vote, what the 503A recommendations mean (September 17, 2026)
AJMC: 5 things to know about the FDA's peptide reversal (August 2026)
Drugs@FDA: FDA-approved drug products